In established mouse glioma models, function-blocking antibodies against CTLA-4 and PD-1 resulted in increased CD8+ T cells, macrophages, and natural killer (NK) cells with decreased regulatory T cells in brain tumor areas, and obtained a durable antitumor activity in mouse models (102–104). This evidence concerns the gene CD8A and brain neoplasm.